NIH is Giving UNC $10M to Research Chlamydia Vaccine

Researchers will receive $10.7 million over five years in hopes of identifying a vaccine candidate for the sexual transmitted infection.

Chlamydia Vaccine / Image: Health Units
Chlamydia Vaccine / Image: Health Units

Chlamydia is curable with oral antibiotics, but it’s still not something you’d ever want to contract. It can lead to infertility and chronic pelvic pain in women and is linked to an increased risk for ovarian cancer. Although it’s the most common bacterial sexually transmitted infection, there is no vaccine to prevent infection. A recent article from Infection Control Today suggested that could all change soon with a hefty investment from the National Institutes of Health (NIH).

The NIH has agreed to give researchers at the University of North Carolina at Chapel Hill, and their colleagues in the US, Europe and Australia, $10.7 million over a span of five years to identify a candidate for the vaccine. The move is part of a larger effort in the fight against sexually transmitted diseases and infections in which four cooperative research centers will receive funding to develop vaccines for chlamydia, syphilis, and gonorrhea.

Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Researched List: Blister Machines for Life Sciences
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
Sustainable Healthcare Packaging Solutions That Work